LITS

SEC source: 0001193125-26-282864 · ownership.xml · nonDerivative · entry 1

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

F1 · price: The price reported is a weighted-average price. These shares were purchased in multiple transactions with prices ranging from $0.8363 to $0.88 per share. The reporting person undertakes to provide Lite Strategy, Inc., any security holders of Lite Strategy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4.

SEC source: 0001193125-26-049089 · ownership.xml · derivative · entry 1

File Justin J. · CIK 0001726277 · Director · CEO, CFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 635,000

Underlying: Common Stock · 455,000 shares

Expires 2035-11-20

F1 · date: The option grant was approved by the LITS board of directors on November 20, 2025, subject to shareholder approval of the 2026 Stock Omnibus Equity Compensation Plan under which the options were granted. LITS shareholders approved the plan on February 12, 2026.

F3 · price: Received as employment compensation.

F2 · derivative.exercise_date: Such option shall be 5.6% vested and exercisable as of the February 12, 2026. The remaining 94.4% shall vest and become exercisable in 34 monthly installments, beginning on February 14, 2026, subject to continued service through the applicable vesting date.

SEC source: 0001193125-25-328666 · ownership.xml · nonDerivative · entry 1

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

F1 · price: The price reported is a weighted-average price. These shares were purchaased in multiple transactions with prices ranging from $1.38 to $1.43 per share. The reporting person undertakes to provide Lite Strategy, Inc., any security holders of Lite Strategy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4.

SEC source: 0001079973-25-001891 · ownership.xml · nonDerivative · entry 1

Schornstein Alexander · CIK 0001999256 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,674,862

F1 · kind: The sales reported on this Form 4 represent shares sold by the reporting person on December 18, 2025, in the open market.

F2 · price: The price reported is the approximate weighted average at which the shares were sold. 690,611 shares were sold on December 18, 2025, in multiple transactions at prices ranging from approximately $1.35 to $1.40. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Upon completion of the sale, the Reporting Person is no longer a 10% owner of the Issuer's shares.

SEC source: 0001193125-25-289712 · ownership.xml · nonDerivative · entry 1

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

F1 · price: The price reported is a weighted-average price. These shares were purchaased in multiple transactions with prices ranging from $1.87 to $1.90 per share. The reporting person undertakes to provide Lite Strategy, Inc., any security holders of Lite Strategy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4.

SEC source: 0001193125-25-286568 · ownership.xml · derivative · entry 1

DRISCOLL FREDERICK W · CIK 0001129890 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-11-14

F2 · price: Received as compensation for service on the Board.

F1 · derivative.exercise_date: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026.

SEC source: 0001193125-25-286429 · ownership.xml · derivative · entry 2

Riezman Joshua · CIK 0002082518 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-11-14

F2 · price: Received as compensation for service on the Board.

F3 · derivative.exercise_date: Customary grant upon appointment of non-employee directors to our Board as revised on November 14, 2025, less options to purchase shares of common stock previously made to Mr. Riezman on August 8, 2025. Such options shall vest and become exercisable in 36 monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

SEC source: 0001193125-25-286429 · ownership.xml · derivative · entry 1

Riezman Joshua · CIK 0002082518 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-11-14

F2 · price: Received as compensation for service on the Board.

F1 · derivative.exercise_date: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026.

SEC source: 0001193125-25-286426 · ownership.xml · derivative · entry 1

File Justin J. · CIK 0001726277 · Director · CEO, CFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 635,000

Underlying: Common Stock · 635,000 shares

Expires 2035-11-14

F2 · price: Received as employment compensation.

F1 · derivative.exercise_date: Such option shall vest and become exercisable in 36 monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

SEC source: 0001193125-25-286427 · ownership.xml · derivative · entry 1

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-11-14

F2 · price: Received as compensation for service on the Board.

F1 · derivative.exercise_date: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026.

SEC source: 0001193125-25-287655 · ownership.xml · derivative · entry 1

Glover Nicholas · CIK 0001578888 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-11-14

F2 · price: Received as compensation for service on the Board.

F1 · derivative.exercise_date: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026.

SEC source: 0001193125-25-290061 · ownership.xml · derivative · entry 1

File Justin J. · CIK 0001726277 · Director · CEO, CFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2035-11-14

F3 · price: Received as employment compensation.

F1 · derivative.exercise_date: Such option shall vest and become exercisable in 36 monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

F2 · derivative.exercise_date: On November 18, 2025, the reporting person filed a Form 4 which inadvertently reported the number options granted to such reporting person. In fact, as reported in this amendment, the reporting person was granted 180,000 options.

SEC source: 0001193125-25-231823 · ownership.xml · derivative · entry 1

Lee Charles Benjamin · CIK 0001751744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-10-03

F1 · derivative.exercise_date: Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

SEC source: 0001193125-25-228265 · ownership.xml · nonDerivative · entry 1

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,900

F1 · price: The price reported is a weighted-average price. These shares were purchaased in multiple transactions with prices ranging from $2.51 to $2.58 per share. The reporting person undertakes to provide Lite Strategy, Inc., any security holders of Lite Strategy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4.

SEC source: 0000929638-25-003120 · form4.xml · derivative · entry 1

Riezman Joshua · CIK 0002082518 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-08-08

F1 · derivative.exercise_date: Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

SEC source: 0000929638-25-002634 · form4.xml · derivative · entry 2

DRISCOLL FREDERICK W · CIK 0001129890 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2035-07-15

F1 · security: Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025.

SEC source: 0000929638-25-002635 · form4.xml · derivative · entry 1

File Justin J. · CIK 0001726277 · Secretary, Acting CEO & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2035-07-15

F1 · security: Customary annual grant to executives of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025.

SEC source: 0000929638-25-002639 · form4.xml · derivative · entry 3

Wood Steven D · CIK 0002001007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2035-07-15

F2 · security: Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025.

SEC source: 0000929638-25-002638 · form4.xml · derivative · entry 2

Reynolds Thomas C · CIK 0001393945 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2035-07-15

F1 · security: Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025.

SEC source: 0000929638-25-002637 · form4.xml · derivative · entry 1

Glover Nicholas · CIK 0001578888 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2035-07-15

F1 · security: Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025.

SEC source: 0000929638-25-002636 · form4.xml · derivative · entry 2

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2035-07-15

F1 · security: Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025.

SEC source: 0000950170-24-062850 · ownership.xml · nonDerivative · entry 1

Wood Steven D · CIK 0002001007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,359

F1 · price: The price reported is a weighted-average price. These shares were purchaased in multiple transactions with prices ranging from $3.10 to $3.18 per share. The reporting person undertakes to provide MEI Pharma, Inc., any security holders of MEI Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4.

SEC source: 0000950170-24-062362 · ownership.xml · nonDerivative · entry 1

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,900

F1 · price: The price reported is a weighted-average price. These shares were purchaased in multiple transactions with prices ranging from $3.11 to $3.21 per share. The reporting person undertakes to provide MEI Pharma, Inc., any security holders of MEI Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4.

SEC source: 0000950170-23-072036 · ownership.xml · derivative · entry 2

Wood Steven D · CIK 0002001007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-12-18

F2 · derivative.exercise_date: Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

SEC source: 0000950170-23-072036 · ownership.xml · derivative · entry 1

Wood Steven D · CIK 0002001007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,700

Underlying: Common Stock · 6,700 shares

Expires 2033-12-18

F1 · derivative.exercise_date: Such option shall be vested and exercisable with respect to 12.5% of the shares on the date of grant and the remainder of the option will vest and become exercisable in equal monthly amounts of 12.5% of the shares subject to the option, beginning on the first day of each calendar month following the date of grant (January 1, 2024) and continuing through July 1, 2024 with full vesting on July 1, 2024, subject to continued service through the applicable vesting date.

SEC source: 0000950170-23-072035 · ownership.xml · derivative · entry 2

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-12-18

F2 · derivative.exercise_date: Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

SEC source: 0000950170-23-072035 · ownership.xml · derivative · entry 1

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,700

Underlying: Common Stock · 6,700 shares

Expires 2033-12-18

F1 · derivative.exercise_date: Such option shall be vested and exercisable with respect to 12.5% of the shares on the date of grant and the remainder of the option will vest and become exercisable in equal monthly amounts of 12.5% of the shares subject to the option, beginning on the first day of each calendar month following the date of grant (January 1, 2024) and continuing through July 1, 2024 with full vesting on July 1, 2024, subject to continued service through the applicable vesting date.

SEC source: 0000950170-24-004228 · ownership.xml · derivative · entry 2

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-12-18

F2 · derivative.exercise_date: Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

SEC source: 0000950170-24-004228 · ownership.xml · derivative · entry 1

Flynn James P · CIK 0001955965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,700

Underlying: Common Stock · 6,700 shares

Expires 2033-12-18

F1 · derivative.exercise_date: Such option shall be vested and exercisable with respect to 12.5% of the shares on the date of grant and the remainder of the option will vest and become exercisable in equal monthly amounts of 12.5% of the shares subject to the option, beginning on the first day of each calendar month following the date of grant (January 1, 2024) and continuing through July 1, 2024 with full vesting on July 1, 2024, subject to continued service through the applicable vesting date.

SEC source: 0000950170-24-004226 · ownership.xml · derivative · entry 2

Wood Steven D · CIK 0002001007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-12-18

F2 · derivative.exercise_date: Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

SEC source: 0000950170-24-004226 · ownership.xml · derivative · entry 1

Wood Steven D · CIK 0002001007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,700

Underlying: Common Stock · 6,700 shares

Expires 2033-12-18

F1 · derivative.exercise_date: Such option shall be vested and exercisable with respect to 12.5% of the shares on the date of grant and the remainder of the option will vest and become exercisable in equal monthly amounts of 12.5% of the shares subject to the option, beginning on the first day of each calendar month following the date of grant (January 1, 2024) and continuing through July 1, 2024 with full vesting on July 1, 2024, subject to continued service through the applicable vesting date.

SEC source: 0000921895-23-002374 · form413392004ans_10242023.xml · derivative · entry 5

Anson Funds Management LP · CIK 0001491072 · 10% owner

Anson Advisors Inc. · CIK 0001581079 · 10% owner

Nathoo Amin · CIK 0001962354 · 10% owner

Kassam Moez · CIK 0001585167 · 10% owner

Anson Management GP LLC · CIK 0001491073 · 10% owner

Winson Bruce Ross · CIK 0001491069 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 671,000 shares

Expires 2023-10-20

F3 · ownership.nature: Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.

SEC source: 0000921895-23-002374 · form413392004ans_10242023.xml · derivative · entry 4

Anson Funds Management LP · CIK 0001491072 · 10% owner

Anson Advisors Inc. · CIK 0001581079 · 10% owner

Nathoo Amin · CIK 0001962354 · 10% owner

Kassam Moez · CIK 0001585167 · 10% owner

Anson Management GP LLC · CIK 0001491073 · 10% owner

Winson Bruce Ross · CIK 0001491069 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 6,710

Underlying: Common Stock · 35,800 shares

Expires 2023-10-20

F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.

F2 · balance_after: Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.nature: Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.

SEC source: 0000921895-23-002374 · form413392004ans_10242023.xml · derivative · entry 3

Anson Funds Management LP · CIK 0001491072 · 10% owner

Anson Advisors Inc. · CIK 0001581079 · 10% owner

Nathoo Amin · CIK 0001962354 · 10% owner

Kassam Moez · CIK 0001585167 · 10% owner

Anson Management GP LLC · CIK 0001491073 · 10% owner

Winson Bruce Ross · CIK 0001491069 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,068

Underlying: Common Stock · 143,200 shares

Expires 2023-10-20

F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.

F2 · balance_after: Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.nature: Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.

SEC source: 0000921895-23-002374 · form413392004ans_10242023.xml · nonDerivative · entry 2

Anson Funds Management LP · CIK 0001491072 · 10% owner

Anson Advisors Inc. · CIK 0001581079 · 10% owner

Nathoo Amin · CIK 0001962354 · 10% owner

Kassam Moez · CIK 0001585167 · 10% owner

Anson Management GP LLC · CIK 0001491073 · 10% owner

Winson Bruce Ross · CIK 0001491069 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,093,188

F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.

F2 · balance_after: Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.nature: Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.

SEC source: 0000921895-23-002374 · form413392004ans_10242023.xml · nonDerivative · entry 1

Anson Funds Management LP · CIK 0001491072 · 10% owner

Anson Advisors Inc. · CIK 0001581079 · 10% owner

Nathoo Amin · CIK 0001962354 · 10% owner

Kassam Moez · CIK 0001585167 · 10% owner

Anson Management GP LLC · CIK 0001491073 · 10% owner

Winson Bruce Ross · CIK 0001491069 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,057,388

F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.

F2 · balance_after: Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.nature: Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.

SEC source: 0000921895-23-002375 · form413392004fun_10242023.xml · derivative · entry 3

Funicular Funds, LP · CIK 0001937147 · 10% owner

Cable Car Capital LLC · CIK 0001699575 · 10% owner

Ma-Weaver Jacob · CIK 0001922140 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Funicular Funds, LP

Disclosed balance after: 0

Underlying: Common Stock · 449,400 shares

Expires 2023-10-20

F1 · ownership.nature: The securities were purchased and are held by Funicular Funds, LP (the "Fund"). Cable Car Capital LLC ("Cable Car"), as the General Partner of the Fund, and Jacob Ma-Weaver, as the Managing Member of Cable Car, may each be deemed the beneficial owner of the shares owned by the Fund. Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

SEC source: 0000921895-23-002375 · form413392004fun_10242023.xml · derivative · entry 2

Funicular Funds, LP · CIK 0001937147 · 10% owner

Cable Car Capital LLC · CIK 0001699575 · 10% owner

Ma-Weaver Jacob · CIK 0001922140 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Funicular Funds, LP

Disclosed balance after: 4,494

Underlying: Common Stock · 120,600 shares

Expires 2023-10-20

F1 · ownership.nature: The securities were purchased and are held by Funicular Funds, LP (the "Fund"). Cable Car Capital LLC ("Cable Car"), as the General Partner of the Fund, and Jacob Ma-Weaver, as the Managing Member of Cable Car, may each be deemed the beneficial owner of the shares owned by the Fund. Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

SEC source: 0000921895-23-002375 · form413392004fun_10242023.xml · nonDerivative · entry 1

Funicular Funds, LP · CIK 0001937147 · 10% owner

Cable Car Capital LLC · CIK 0001699575 · 10% owner

Ma-Weaver Jacob · CIK 0001922140 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Funicular Funds, LP

Disclosed balance after: 611,440

F1 · ownership.nature: The securities were purchased and are held by Funicular Funds, LP (the "Fund"). Cable Car Capital LLC ("Cable Car"), as the General Partner of the Fund, and Jacob Ma-Weaver, as the Managing Member of Cable Car, may each be deemed the beneficial owner of the shares owned by the Fund. Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

SEC source: 0000921895-23-002339 · form413392004ans_10132023.xml · derivative · entry 4

Anson Funds Management LP · CIK 0001491072 · 10% owner

Anson Advisors Inc. · CIK 0001581079 · 10% owner

Nathoo Amin · CIK 0001962354 · 10% owner

Kassam Moez · CIK 0001585167 · 10% owner

Anson Management GP LLC · CIK 0001491073 · 10% owner

Winson Bruce Ross · CIK 0001491069 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 8,500

Underlying: Common Stock · 10,000 shares

Expires 2023-10-20

F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.

F2 · balance_after: Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.nature: Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.

SEC source: 0000921895-23-002339 · form413392004ans_10132023.xml · derivative · entry 3

Anson Funds Management LP · CIK 0001491072 · 10% owner

Anson Advisors Inc. · CIK 0001581079 · 10% owner

Nathoo Amin · CIK 0001962354 · 10% owner

Kassam Moez · CIK 0001585167 · 10% owner

Anson Management GP LLC · CIK 0001491073 · 10% owner

Winson Bruce Ross · CIK 0001491069 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 8,600

Underlying: Common Stock · 40,000 shares

Expires 2023-10-20

F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.

F2 · balance_after: Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.nature: Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.

SEC source: 0000921895-23-002339 · form413392004ans_10132023.xml · nonDerivative · entry 2

Anson Funds Management LP · CIK 0001491072 · 10% owner

Anson Advisors Inc. · CIK 0001581079 · 10% owner

Nathoo Amin · CIK 0001962354 · 10% owner

Kassam Moez · CIK 0001585167 · 10% owner

Anson Management GP LLC · CIK 0001491073 · 10% owner

Winson Bruce Ross · CIK 0001491069 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 914,188

F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.

F2 · balance_after: Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.nature: Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.

SEC source: 0000921895-23-002339 · form413392004ans_10132023.xml · nonDerivative · entry 1

Anson Funds Management LP · CIK 0001491072 · 10% owner

Anson Advisors Inc. · CIK 0001581079 · 10% owner

Nathoo Amin · CIK 0001962354 · 10% owner

Kassam Moez · CIK 0001585167 · 10% owner

Anson Management GP LLC · CIK 0001491073 · 10% owner

Winson Bruce Ross · CIK 0001491069 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 904,188

F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.

F2 · balance_after: Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.nature: Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.

SEC source: 0000921895-23-002340 · form413392004fun_10132023.xml · derivative · entry 2

Funicular Funds, LP · CIK 0001937147 · 10% owner

Cable Car Capital LLC · CIK 0001699575 · 10% owner

Ma-Weaver Jacob · CIK 0001922140 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Funicular Funds, LP

Disclosed balance after: 5,700

Underlying: Common Stock · 30,000 shares

Expires 2023-10-20

F1 · ownership.nature: The securities were purchased and are held by Funicular Funds, LP (the "Fund"). Cable Car Capital LLC ("Cable Car"), as the General Partner of the Fund, and Jacob Ma-Weaver, as the Managing Member of Cable Car, may each be deemed the beneficial owner of the shares owned by the Fund. Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

SEC source: 0000921895-23-002340 · form413392004fun_10132023.xml · nonDerivative · entry 1

Funicular Funds, LP · CIK 0001937147 · 10% owner

Cable Car Capital LLC · CIK 0001699575 · 10% owner

Ma-Weaver Jacob · CIK 0001922140 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Funicular Funds, LP

Disclosed balance after: 490,840

F1 · ownership.nature: The securities were purchased and are held by Funicular Funds, LP (the "Fund"). Cable Car Capital LLC ("Cable Car"), as the General Partner of the Fund, and Jacob Ma-Weaver, as the Managing Member of Cable Car, may each be deemed the beneficial owner of the shares owned by the Fund. Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

SEC source: 0000929638-23-002773 · form4.xml · derivative · entry 1

DRISCOLL FREDERICK W · CIK 0001129890 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-09-29

F1 · derivative.exercise_date: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

SEC source: 0000929638-23-002767 · form4.xml · derivative · entry 1

GHALIE RICHARD G · CIK 0001156208 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-09-29

F1 · derivative.exercise_date: One quarter of such options shall vest as of July 1, 2024, with monthly vesting on the first day of each of the next 36 calendar months beginning on August 1, 2024.

SEC source: 0000929638-23-002771 · form4.xml · derivative · entry 1

GOLD DANIEL P PHD · CIK 0001288233 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-09-29

F1 · derivative.exercise_date: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

SEC source: 0000929638-23-002774 · form4.xml · derivative · entry 1

Baltic Charles V. III · CIK 0001533340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-09-29

F1 · security: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · derivative.exercise_price: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · date: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · deemedExecutionDate: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · kind: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · shares: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · price: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · derivative.exercise_date: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · derivative.expiration_date: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · derivative.underlying: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · derivative.underlying_shares: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · balance_after: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · ownership.direct: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

F1 · ownership.nature: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

SEC source: 0000929638-23-002772 · form4.xml · derivative · entry 1

Glover Nicholas · CIK 0001578888 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-09-29

F1 · derivative.exercise_date: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.